4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

计划入组 480 人 · 首次发布于 2025 年 3 月 7 日

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

计划入组 480 人 · 首次发布于 2025 年 7 月 15 日

Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

计划入组 30 人 · 首次发布于 2025 年 9 月 23 日

Anti-Neovascularization (Reglagene)

Verteporfin(Visudyne)

C₄₁H₄₂N₄O₈ · Rx

UF-61-QB443

Optiva Inc

Australia

Ocugen

United States

Rezolute

United States

First Comprehensive Post-Marketing Safety Comparison Reveals Differing Adverse Event Profiles for Geographic Atrophy Treatments

Samsung Bioepis' OfubizTM (Aflibercept) Biosimilar Approved in Europe for Ophthalmic Diseases

Five-Year Study Shows Aflibercept Treat-and-Extend Regimen Maintains Vision in Neovascular AMD Patients